Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

4514 - Establishing the Need for Immuno-oncology (IO) Therapy (tx) in Second-Line (2L) Small Cell Lung Cancer (SCLC)

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Immunotherapy

Tumour Site

Presenters

Lee Schwartzberg

Citation

Annals of Oncology (2018) 29 (suppl_8): viii400-viii441. 10.1093/annonc/mdy288

Authors

L. Schwartzberg1, J.R. Penrod2, Y. Yuan2, T. Gu2, T..K. Le3, P. Abraham2, B. Korytowsky2, G. Selvaggi2

Author affiliations

  • 1 Oncology, West Cancer Center, 38138 - Germantown/US
  • 2 Worldwide Health Economics & Outcomes Research, Bristol-Myers Squibb, Princeton/US
  • 3 Center For Observational Research & Data Sciences, Bristol-Myers Squibb, Princeton/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4514

Background

2L tx for SCLC is heavily dependent on 1L platinum (PT) response. NCCN guidelines recommend PT retreatment if recurrence is > 3-6 months post 1L PT; while alternative options should be considered for rapid relapse (topotecan [TOP] in 2L PT-resistant). In 2016, nivolumab (NIVO) +/- ipilimumab (IPI), were added to 2L NCCN guidelines. This study evaluates 2L SCLC patterns of care and outcomes and attempts to contextualize CheckMate 032 data by creating a matched real-world comparator.

Methods

Adult SCLC pts receiving systemic tx from the Flatiron Health database were selected (01Jan2011-30Sep2017). Index date was SCLC diagnosis (dx). Pts were included if: not on clinical trial; no secondary malignancy within 3 years (y); no IO use; and ≥2 months (mo) of medical data on/after dx. PT sensitivity was based on a 90 day gap. Median, 1-y and 2-y overall survival (OS) by Kaplan-Meier was calculated from 2L initiation to death. Median duration of therapy (mDoT) was assessed. A matched 2L cohort was constructed using CheckMate 032 Inclusion/Exclusion criteria (I/E).

Results

2,056 pts initiated 1L tx (full cohort), of which 628 pts went on to 2L; 42% received TOP and 58% other txs. Within 2L, mean age was 65y; 69% were white, 51% were female, 98% had a smoking history and 95% were treated in the community. Of 2L pts, 68% had extensive and 27% had limited disease at dx. 372 were PT-sensitive and 231 pts were PT-resistant. Upon matching for CheckMate 032 I/E, 903 pts were identified of whom 254 initiated 2L. For the full and matched cohorts respectively, 2L mDoT for TOP was 2.0 mo (SD = 2.5) and 2.2 mo (SD = 2.7) and for other tx was 2.6 mo (SD = 2.2) and 2.8 mo (2.4). Median, 1-y and 2-y OS results for the full/ matched cohorts and CheckMate 032 are shown (Table).Table: 1214P

Overall survival from diagnosis and 2L initiation in Flatiron Health and CheckMate 032

median OS, months [95%CI]1-year / 2-year survival (%)
FULL COHORT
From Diagnosis
All (N = 2056)11.6 [11.1,12.3]48.6/ 22.0
Limited disease (n = 680)19.6 [18.0,21.5]71.9/ 42.3
Extensive disease (n = 1,263)9.4 [8.9,9.9]35.2/ 10.5
From Initiation of 2L
All (n = 628)4.2 [3.7,4.7]13.3/ 3.3
PT-sensitive (n = 372)5.4 [4.4,6.2]15.9/ 4.2
PT-refractory (n = 231)3.0 [2.6,3.6]9.1/ 2.9
MATCHED COHORT
From Diagnosis
All (N = 903)12.5 [11.5,14.3]47.0/ 26.4
Limited disease (n = 348)23.8 [20.0,29.5]72.0/ 49.5
Extensive disease (n = 507)9.8 [8.9,10.6]37.9/ 12.1
From Initiation of 2L
All (n = 254)4.9 [4.0,6.2]14.6/ 3.8
PT-sensitive (n = 158)6.3 [5.6,7.5]18.4/ 6.0
PT-refractory (n = 90)2.7 [2.1,3.3]5.6/ 1.9
CHECKMATE 032
NIVO 3 mg/kg cohort (n = 98)4.4 [3.0–9.3]33/ NR
NIVO 1 mg/kg + IPI 3 mg/kg (n = 61)7.7 [3.6–18.0]43/ NR
NIVO 3 mg/kg + IPI 1 mg/kg (n = 54)6.0 [3.6–11.0]35/ NR
*

NR=not reported; PT=platinum; NIVO=nivolumab; IPI=ipilimumab

Conclusions

This large retrospective data set highlighting 2L SCLC outcomes demonstrates poor survival in this setting underscoring the need for novel tx. Results from CheckMate 032 present IO as a potential option for SCLC pts.

Clinical trial identification

NA

Legal entity responsible for the study

Bristol-Myers Squibb.

Funding

Bristol-Myers Squibb.

Editorial Acknowledgement

This study was funded by Bristol-Myers Squibb, Inc. All authors contributed to and approved the presentation. Editorial assistance was provided by PAREXEL, funded by Bristol-Myers Squibb.

Disclosure

L. Schwartzberg: Consultant: Bristol-Myers Squibb, Merck, Pfizer, Astra Zeneca, Amgen. J.R. Penrod, Y. Yuan, T. Gu, T.K. Le, P. Abraham, B. Korytowsky, G. Selvaggi: Employee, Stock ownership: Bristol-Myers Squibb.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.